Last updated: 2026-09-06 08:40:00. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Spyre Therapeutics, Inc. (SYRE) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $89.04, with a market capitalisation of $7.85B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $14.51 to $110.18. This page covers its latest market performance, valuation, price trends and company information.
$7.85B | |
$86.45 | |
$110.18 | |
$10.42 | |
$87.25 | |
594.49K | |
1.31M | |
-- | |
$110.18 | |
$14.51 | |
-- | |
-- |
Spyre Therapeutics, Inc. (SYRE) last closed at $87.25 as of 2026-09-04 23:31:00, unchanged from the previous close of $87.25.
During the latest regular trading session, SYRE traded between $10.42 and $110.18, with a volume of 594.49K shares. The closing price was near the upper end and near the upper end of its 52-week range.
Over the past seven days, Spyre Therapeutics, Inc. (SYRE) moved from $93.62 to $89.04, representing a decline of 4.88% ($4.57).
The stock traded between $84.00 and $94.95 during the period. The latest price is near the middle of the 7-day range, indicating moderate downward.
The average daily volume was 1.28 million shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 77.9%
SYRE is currently trading at $89.04, placing it 77.9% of the way from its 52-week low of $14.51 to its 52-week high of $110.18. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Spyre Therapeutics Inc is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases. Spyre's pipeline includes extended half-life antibodies targeting α4β7, TL1A, and IL-23 in development as monotherapies and pair-wise combinations. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 112 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Spyre Therapeutics, Inc. (SYRE) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.